Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Favipiravir  COVID-19 treatment studies for Favipiravir  C19 studies: Favipiravir  Favipiravir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 16% Improvement Relative Risk Ventilation 10% c19early.org/a Acar Sevinc et al. NCT04645433 Favipiravir ICU Is very late treatment with favipiravir beneficial for COVID-19? Retrospective 100 patients in Turkey (March - May 2020) Study compares with lopinavir/ritonavir, results vs. placebo may differ Lower mortality with favipiravir (not stat. sig., p=0.38) Acar Sevinc, S., SiSli Etfal Hastanesi Tip Bulte.., doi:10.14744/SEMB.2021.35902 Favors favipiravir Favors lopinavir/ri..
Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit
Acar Sevinc, S., SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital, doi:10.14744/SEMB.2021.35902, NCT04645433 (history)
Acar Sevinc, Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit, , S., SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital, doi:10.14744/SEMB.2021.35902, NCT04645433
Jun 2022   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 100 ICU patients in Turkey, showing improved survival with favipiravir vs. lopinavir/ritonavir. This study is excluded in the after exclusion results of meta analysis: very late stage, ICU patients.
risk of death, 16.2% lower, RR 0.84, p = 0.38, treatment 57 of 85 (67.1%), control 12 of 15 (80.0%), NNT 7.7.
risk of mechanical ventilation, 10.3% lower, RR 0.90, p = 0.75, treatment 61 of 85 (71.8%), control 12 of 15 (80.0%), NNT 12.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Acar Sevinc et al., 28 Jun 2022, retrospective, Turkey, peer-reviewed, mean age 65.6, 1 author, study period 10 March, 2020 - 10 May, 2020, this trial compares with another treatment - results may be better when compared to placebo, trial NCT04645433 (history).
Contact: sultanacar34@hotmail.com.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperFavipiravirAll
Abstract: THE MEDICAL BULLETIN OF SISLI ETFAL HOSPITAL DOI: 10.14744/SEMB.2021.35902 Med Bull Sisli Etfal Hosp 2022;56(2):189–195 Original Research Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit Sultan Acar Sevinc,1 Ayse Surhan Cinar,1 Nermin Balta Basi,1 Serkan Islamoglu,1 Mustafa Altinay,1 Haci Mustafa Ozdemir2 Seyhan Metin,1 Tugba Yucel,1 Department of Anesthesiology and Reanimation, University of Health Sciences Turkey, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey 2 Department of Orthopedics, University of Health Sciences Turkey, Sisli Hamidiye Etfal Training and Research Hospital, Istanbul, Turkey 1 Abstract Objectives: The aim of this study was to compare intensive care unit (ICU) and overall hospital mortality in patients treated with favipiravir and lopinavir-ritonavir for COVID-19. Methods: Data were collected retrospectively between March 10 and May 10, 2020, from patients’ records admitted to ICU due to COVID-19. Laboratory data, clinical characteristics, ICU and hospital mortality, ICU and hospital length of stay were compared in patients treated with favipiravir and lopinavir-ritonavir. Results: A total of 100 patients’ data were investigated. Favipiravir was used as the treatment for 85% of patients, with the rest treated with lopinavir-ritonavir. Clinical and laboratory data of both antiviral treatment groups were similar. Length of hospital stay was 16 (9–24) days with favipiravir and 8.5 (5–12.5) days with lopinavir-ritonavir (p=0.002). Length of ICU stay for favipiravir and lopinavir-ritonavir groups were 8 (5–15) days and 4 (3–9) days, respectively (p=0.011). ICU mortality was 65.9% for the favipiravir and 80% for lopinavir-ritonavir (p=0.002). Hospital mortality for favipiravir and lopinavir-ritonavir was 67.1% and 80%, respectively (p=0.001). Conclusion: The mortality in patients treated with favipiravir was less than patients treated with lopinavir-ritonavir. Favipiravir needs more attention and trials for its effect to be confirmed. Keywords: COVID-19, intensive care unit, favipiravir, lopinavir-ritonavir, mortality Please cite this article as ”Acar Sevinc S, Surhan Cinar A, Balta Basi N, Metin S, Yucel T, Islamoglu S, et al. Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit. Med Bull Sisli Etfal Hosp 2022;56(2):189–195”. C OVID-19 is the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and may present in different clinical scenarios: About 80% of patients present with mild, 13.8% present with severe disease, and 6.1% with critical disease.[1] According to the guidelines published by the Ministry of Health in Turkey, patients with severe and critical disease were advised to be admitted to intensive care unit (ICU).[2] Turkey diagnosed Address for correspondence: Sultan Acar Sevinc, MD. Sisli Hamidiye Etfal Egitim ve Arastirma Hastanesi, Anesteziyoloji ve Reanimasyon Bolumu, Istanbul, Turkey Phone: +90 212 373 50 00 E-mail: sultanacar34@hotmail.com Submitted Date: July 13, 2021 Accepted Date: September 18, 2021 Available Online Date: June 28, 2022 © Copyright 2022 by The Medical Bulletin of Sisli Etfal Hospital - Available online at www.sislietfaltip.org OPEN ACCESS This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/). 190 its first COVID-19 case on March 11, 2020. A detailed treatment algorithm was published on April 14,..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit